120 related articles for article (PubMed ID: 37713975)
21. CD47 Overexpression Is Associated with Epstein-Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma.
Wang ZH; Pei XF; Zhu ZQ; Lin Z; Mao YY; Xu XL; Luo YL; Zhang L; Peng PJ
Onco Targets Ther; 2020; 13():3325-3334. PubMed ID: 32368091
[TBL] [Abstract][Full Text] [Related]
22. Integrated mRNA and microRNA transcriptome sequencing characterizes sequence variants and mRNA-microRNA regulatory network in nasopharyngeal carcinoma model systems.
Szeto CY; Lin CH; Choi SC; Yip TT; Ngan RK; Tsao GS; Li Lung M
FEBS Open Bio; 2014; 4():128-40. PubMed ID: 24490137
[TBL] [Abstract][Full Text] [Related]
23. Silencing c-Jun inhibits autophagy and abrogates radioresistance in nasopharyngeal carcinoma by activating the PI3K/AKT/mTOR pathway.
Sun Y; Chen K; Lin G; Wan F; Chen L; Zhu X
Ann Transl Med; 2021 Jul; 9(13):1085. PubMed ID: 34422997
[TBL] [Abstract][Full Text] [Related]
24. Oral Microbiota Alteration and Roles in Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma.
Liao Y; Zhang JB; Lu LX; Jia YJ; Zheng MQ; Debelius JW; He YQ; Wang TM; Deng CM; Tong XT; Xue WQ; Cao LJ; Wu ZY; Yang DW; Zheng XH; Li XZ; Wu YX; Feng L; Ye W; Mu J; Jia WH
Microbiol Spectr; 2023 Feb; 11(1):e0344822. PubMed ID: 36645283
[TBL] [Abstract][Full Text] [Related]
25. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells.
Cai Y; Xia Q; Su Q; Luo R; Sun Y; Shi Y; Jiang W
Int J Mol Med; 2013 Apr; 31(4):904-12. PubMed ID: 23426850
[TBL] [Abstract][Full Text] [Related]
26. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
Yang F; Qian XJ; Qin W; Deng R; Wu XQ; Qin J; Feng GK; Zhu XF
PLoS One; 2013; 8(3):e59879. PubMed ID: 23533654
[TBL] [Abstract][Full Text] [Related]
27. Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models.
Lam RCT; Hui CWC; Wong CH; Lo KW; Tsang ACM; Hui EP; Chan ATC; Ma BBY
Invest New Drugs; 2023 Oct; 41(5):699-709. PubMed ID: 37572231
[TBL] [Abstract][Full Text] [Related]
28. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy.
Liu WN; Fong SY; Tan WWS; Tan SY; Liu M; Cheng JY; Lim S; Suteja L; Huang EK; Chan JKY; Iyer NG; Yeong JPS; Lim DW; Chen Q
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331230
[TBL] [Abstract][Full Text] [Related]
29. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
[TBL] [Abstract][Full Text] [Related]
30. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
[TBL] [Abstract][Full Text] [Related]
31. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus nuclear antigen 1 (EBNA1) protein induction of epithelial-mesenchymal transition in nasopharyngeal carcinoma cells.
Wang L; Tian WD; Xu X; Nie B; Lu J; Liu X; Zhang B; Dong Q; Sunwoo JB; Li G; Li XP
Cancer; 2014 Feb; 120(3):363-72. PubMed ID: 24190575
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties.
Zhu N; Wang Q; Wu Z; Wang Y; Zeng MS; Yuan Y
J Virol; 2022 Mar; 96(5):e0194121. PubMed ID: 35019715
[TBL] [Abstract][Full Text] [Related]
34. EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer.
Soldan SS; Anderson EM; Frase DM; Zhang Y; Caruso LB; Wang Y; Deakyne JS; Gewurz BE; Tempera I; Lieberman PM; Messick TE
Gastric Cancer; 2021 Sep; 24(5):1076-1088. PubMed ID: 33929613
[TBL] [Abstract][Full Text] [Related]
35. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
36. Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma.
Zhao YY; Tian Y; Liu L; Zhan JH; Hou X; Chen X; Zhou T; Huang Y; Zhang L
Drug Des Devel Ther; 2018; 12():2655-2663. PubMed ID: 30214154
[TBL] [Abstract][Full Text] [Related]
37. The Epstein-Barr virus-encoded microRNA MiR-BART9 promotes tumor metastasis by targeting E-cadherin in nasopharyngeal carcinoma.
Hsu CY; Yi YH; Chang KP; Chang YS; Chen SJ; Chen HC
PLoS Pathog; 2014 Feb; 10(2):e1003974. PubMed ID: 24586173
[TBL] [Abstract][Full Text] [Related]
38. Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma.
Hau PM; Lung HL; Wu M; Tsang CM; Wong KL; Mak NK; Lo KW
Front Oncol; 2020; 10():600. PubMed ID: 32528868
[TBL] [Abstract][Full Text] [Related]
39. Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts.
Lin YT; Wang HC; Chuang HC; Hsu YC; Yang MY; Chien CY
J Mol Med (Berl); 2018 Dec; 96(12):1407-1418. PubMed ID: 30374682
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.
Ren Q; Sato H; Murono S; Furukawa M; Yoshizaki T
Laryngoscope; 2004 May; 114(5):855-9. PubMed ID: 15126743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
